Human Immunodeficiency Virus (HIV) - Current and Future Players Summary GlobalData has released its pharma report, “Human Immunodeficiency Virus (HIV) - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Human Immunodeficiency Virus (HIV) Market. The report identifies and analyses the key companies shaping and driving the global Human Immunodeficiency Virus (HIV) market. The report provides insight into the competitive Human Immunodeficiency Virus (HIV) landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase. Scope - Investigation of current and future market competition for Human Immunodeficiency Virus (HIV) - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of Human Immunodeficiency Virus (HIV) sector through market impact analysis, future market scenario and company... Research Beam Model: Research Beam Product ID: 725702 2995 USD New
Human Immunodeficiency Virus (HIV) - Current and Future Players
 
 

Human Immunodeficiency Virus (HIV) - Current and Future Players

  • Category : Pharmaceuticals
  • Published On : September   2015
  • Pages : 132
  • Publisher : GlobalData
 
 
 
Human Immunodeficiency Virus (HIV) - Current and Future Players

Summary

GlobalData has released its pharma report, “Human Immunodeficiency Virus (HIV) - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Human Immunodeficiency Virus (HIV) Market. The report identifies and analyses the key companies shaping and driving the global Human Immunodeficiency Virus (HIV) market. The report provides insight into the competitive Human Immunodeficiency Virus (HIV) landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

- Investigation of current and future market competition for Human Immunodeficiency Virus (HIV)
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of Human Immunodeficiency Virus (HIV) sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving Human Immunodeficiency Virus (HIV) market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What’s the next big thing in the global Human Immunodeficiency Virus (HIV) market landscape? Identify, understand and capitalize
Table Of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Introduction 6
2.1 Catalyst 6
2.2 Related Reports 7
2.3 Upcoming Related Reports 7
3 Market Outlook 8
3.1 Global Markets 8
3.1.1 Forecast 8
3.1.2 Drivers and Barriers - Global Issues 14
4 Current and Future Players 17
4.1 Overview 17
4.2 Trends in Corporate Strategy 19
4.3 Company Profiles 21
4.3.1 Gilead Sciences 21
4.3.2 ViiV Healthcare 26
4.3.3 AbbVie 31
4.3.4 Merck & Co. 34
4.3.5 Janssen 38
4.3.6 Bristol-Myers Squibb 42
4.3.7 Japan Tobacco 47
4.3.8 Avexa 50
4.3.9 TaiMed Biologics 53
4.3.10 Tobira Therapeutics 55
5 Appendix 59
5.1 Bibliography 59
5.2 Abbreviations 93
5.3 Methodology 100
5.4 Forecasting Methodology 100
5.4.1 Total Prevalent Cases of HIV 100
5.4.2 20-Year Diagnosed Prevalent Cases of HIV 100
5.4.3 HIV Cases Treated with ART 101
5.4.4 Drugs Included in Each Therapeutic Class 102
5.4.5 Launch and Patent Expiry Dates 103
5.4.6 General Pricing Assumptions 104
5.4.7 Individual Drug Assumptions 106
5.4.8 Generic Erosion 124
5.4.9 Pricing of Pipeline Agents 124
5.5 Primary Research - KOLs Interviewed for This Report 126
5.6 Primary Research - Prescriber Survey 128
5.7 About the Authors 129
5.7.1 Analyst 129
5.7.2 Epidemiologists 129
5.7.3 Therapy Area Director 129
5.7.4 Global Director of Therapy Analysis and Epidemiology 130
5.7.5 Global Head of Healthcare 130
5.8 About GlobalData 131
5.9 Disclaimer 131

List Of Tables
1.1 List of Tables
Table 1: Global Sales Forecasts ($m) for HIV Therapeutics, 2013-2023 10
Table 2: Global HIV Therapeutics Market - Drivers and Barriers, 2013-2023 14
Table 3: Key Companies in the HIV-1 Market in the 9MM, 2014 18
Table 4: Gilead Sciences’ HIV Portfolio Assessment, 2014 25
Table 5: Gilead Sciences, SWOT Analysis in HIV, 2013-2023 26
Table 6: ViiV Healthcare’s HIV Portfolio Assessment, 2014 30
Table 7: ViiV Healthcare, SWOT Analysis in HIV, 2013-2023 31
Table 8: AbbVie’s HIV Portfolio Assessment, 2014 33
Table 9: AbbVie, SWOT Analysis in HIV, 2013-2023 34
Table 10: Merck & Co.’s HIV Portfolio Assessment, 2014 37
Table 11: Merck & Co., SWOT Analysis in HIV, 2013-2023 38
Table 12: Janssen’s HIV Portfolio Assessment, 2014 41
Table 13: Janssen, SWOT Analysis in HIV, 2013-2023 42
Table 14: BMS’ HIV Portfolio Assessment, 2014 46
Table 15: BMS, SWOT Analysis in HIV, 2013-2023 47
Table 16: Japan Tobacco’s HIV Portfolio Assessment, 2014 49
Table 17: Japan Tobacco, SWOT Analysis in HIV, 2013-2023 49
Table 18: Avexa’s HIV Portfolio Assessment, 2014 52
Table 19: Avexa, SWOT Analysis in HIV, 2013-2023 52
Table 20: TaiMed Biologics, HIV Portfolio Assessment, 2014 54
Table 21: TaiMed Biologics, SWOT Analysis in HIV, 2013-2023 55
Table 22: Tobira Therapeutics, HIV Portfolio Assessment, 2014 57
Table 23: Tobira Therapeutics, SWOT Analysis in HIV, 2013-2023 58
Table 24: Key Historical and Projected Launch Dates for HIV Therapeutics Across the 9MM 103
Table 25: Key Historical and Projected Patent Expiry Dates for HIV Therapeutics Across the 9MM 104
Table 26: High-Prescribing Physicians (non-KOLs) Surveyed, by Country 128

List Of Figures
1.2 List of Figures
Figure 1: Global Sales for HIV Therapeutics by Country, 2013-2023 12
Figure 2: Global Sales for HIV Therapeutics by Drug Class, 2013-2023 13
Figure 3: Company Portfolio Gap Analysis in HIV, 2013-2023 19
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter

 
 
REQUEST SAMPLE    ASK FOR DISCOUNT